Current Oncology Author Survey Results At Multimed Inc., we strive to offer authors a great publishing experience. We created a survey to obtain feed

CO-NEWSLETTER-LOGO June2013

Current Oncology Author Survey Results

At Multimed Inc., we strive to offer authors a great publishing experience. We created a survey to obtain feedback and comments from our authors, which included the following areas:

• Experience of the publishing process with Current Oncology
• What is important to them when deciding where to publish
• Important databases and indexing services

The online survey was sent to 2,491 Current Oncology authors. We received a total of 202 (8.1%) responses. The survey was open from April 2, 2013 – April 30, 2013.

We are pleased to report that 89% of authors were highly satisfied or satisfied with the overall publishing experience!

To view the survey results and key findings visit the following link:

http://mad.ly/b6cfc3

It is through surveys that we are able to assess our progress and identify future opportunities for improvement. We are grateful to those who took the time to complete the survey.

With the results received, our goal is to continue to improve the experience of authors publishing with Current Oncology, while maintaining the high standards of the journal.

tom.oliver

All participants who completed the survey were entered into a draw for a chance to win an iPad mini. The winner of the iPad mini is Dr. Tom Oliver (pictured right). Congratulations!

Multimed-clean

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
CO Twitter Banner Ad
***
InPress-CON

Volume 20, Number 3 (June 2013)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:
http://www.current-oncology.com/index.php/oncology/issue/current/showToc

This issue contains a series on the role of bilateral salpingectomy in preventing high grade serous ovarian carcinoma. Click on the article titles below to view articles from this special series!

Preventing ovarian cancer by salpingectomy
Editorial by W. Foulkes

Opportunistic salpingectomy: the way forward
Guest Editorial by D. Miller et al.

Salpingectomy to prevent ovarian cancer
Countercurrents by S. Narod

Fallopian tube removal: “STIC-ing” it to ovarian cancer: what is the utility of prophylactic tubal removal?
Commentary by T. Herzog et al.

Examining the use of salpingectomy with hysterectomy in Canada
Cancer System Indicator Snapshots by Sandoval et al.

***
LookingAhead-CON

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 20, Number 4 (August 2013) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC

***
EditorSpotlight
Dr. William Foulkes Official

Dr. Will Foulkes, MB BS PhD
Editor of our Cancer Genetics Section (since February 2009)

Dr. Will Foulkes is Director of the Program in Cancer Genetics, based at McGill University in the Departments of Oncology and Human Genetics. He is also head of the Cancer Genetics Laboratory at the Lady Davis Institute for Medical Research. He is a James McGill Professor of Medicine, Human Genetics and Oncology at McGill University, and holds a FRSQ Chercheur national award. His work has focused on inherited susceptibility to cancer, mainly of the breast and colorectum. He is a clinician, who has been in charge of clinical cancer genetics at all McGill-affiliated hospitals since 1996.

He is best known for his work on the clinico-pathological features of hereditary breast cancer, for his discovery of a founder mutation in MSH2 in the Ashkenazim, and for his identification of a founder mutation in the breast cancer susceptibility gene PALB2. He has also collaborated extensively with researchers around the world to better understand the genetics of breast, colorectal, prostate, pancreatic, and ovarian cancer.

He has been the scientific organizer of the Montreal-based biennial Hereditary Breast and Ovarian Cancer conference since its inception in 2005. At the last conference, over 400 attended the three-day meeting.

Dr. Foulkes’ lab works on several aspects of inherited susceptibility to cancer, often generating data from individuals and families that present at his clinic. He is particularly interested in following up single families with unusual phenotypes. He is currently working on susceptibility to breast, colon, and ovarian neoplasms.

***
HaveYouHeard-CON

Current Oncology Welcomes New Members to our Editorial Team

We are pleased to announce the following new members to the Current Oncology Editorial team:
• Dr. Sharlene Gill, British Columbia Cancer Agency, Vancouver, BC (Section Editor, Medical Oncology)
• Dr. Jason Park, St. Boniface General Hospital, Winnipeg, MB (Section Editor, Oncology Education)
• Dr. Winson Cheung, UBC Division of Medical Oncology and British Columbia Cancer Agency, Vancouver, BC (Section Editor, Geriatric Oncology)

Current Oncology is a Canadian Publication with International Exposure

In our recent survey to authors, the international reach of the journal was a Top 5 important factor for our authors when deciding where to publish. Publishing with Current Oncology will provide international exposure as exemplified by:
www.current-oncology.com is visited by 128 countries (28% USA, 27% Canada and 45% Int’l)
• Over 11,000 website visits per month; an 86% increase from 2012 (Google Analytics, April 2013)
• Over 47,000 article views in PubMed Central in April 2013 (82% increase from April 2012)

Current Oncology is an Open Access Publication

Current Oncology publishes under an Open Access publication model, where immediately upon publication all articles are freely available and searchable for all users without any subscription or access barriers. Under a subscription-based model, publication costs are primarily covered by charging libraries and individuals for access to the journal's content through subscriptions. Under Current Oncology’s Open Access model, we aim to cover the costs of publication primarily through a combination of author fees and industry support.

We believe our model provides the author’s work with the highest visibility and maximum exposure. The funds received allows Current Oncology to continue to publish in Open Access format, and provide a high quality publication with a rigorous peer review process and international reach through inclusion in major databases.

Multimed Inc., is pleased to support the Bruyère Foundation!

Multimed Inc., is pleased to support the Bruyère Foundation through their Palliative Rehabilitation Research program. The aim of this program is to prolong and improve quality-of-life amongst patients with cancer. Dr. Martin Chasen, the Managing Editor for Current Oncology, is leading the rehabilitation program, which also integrates research components. The eight-week palliative rehabilitation program provides physiotherapy and occupational therapy as well as consultations with a physician, nurse, social worker and dietitian to aid in the mental and physical recovery of patients.

Multimed is proud to contribute to the Palliative Rehabilitation Research program’s efforts to improve both patient care and the knowledge of palliative care within the medical community.

***
ReadersChoice-COn

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (May 2013)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M
Curr Oncol. 2009 Jan;16(1):16-26

Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature
Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C.
Curr Oncol. 2010 Aug;17(4):94-112

Most Read Recently* Published Articles at www.current-oncology.com

A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
Van der Jagt R, Laneuville P, Macdonald D, Stewart D, Christofides A, Sehn LH.
Curr Oncol. 2012 Jun;19(3):160-8

International variability in the reimbursement of cancer drugs by publically funded drug programs
Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME
Curr Oncol. 2012 Jun;19(3):e165-76

Casting stones and casting aspersions: let's not lose sight of the main issues in the euthanasia debate
Pereira J.
Curr Oncol. 2012 Jun;19(3):139-42

*Published within past 12 months

***
QuickLinks-CON
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px